AbbVie (ABBV) Net Cash Flow (2012 - 2026)

AbbVie (ABBV) has reported Net Cash Flow for 15 consecutive years, with -$2.8 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Net Cash Flow fell 323.06% year-over-year to -$2.8 billion in Q2 2026; TTM through Jun 2026 was $118.0 million, a 101.77% increase from a year earlier, with the FY2025 full-year figure at -$337.0 million, up 95.34% from the prior year.
• Net Cash Flow was -$2.8 billion for Q2 2026 at AbbVie, down from $4.2 billion in the prior quarter.
• Over five years, Net Cash Flow peaked at $5.3 billion in Q1 2024 and troughed at -$5.9 billion in Q3 2024.
• A 5-year average of -$171.0 million and a median of -$453.5 million in 2023 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow plunged 368.55% in 2022 and jumped 1265.92% in 2026, its largest moves.
• Over 5 years, Net Cash Flow stood at -$2.7 billion in 2022, then soared by 81.31% to -$496.0 million in 2023, then slumped by 240.12% to -$1.7 billion in 2024, then soared by 75.64% to -$411.0 million in 2025, then tumbled by 584.91% to -$2.8 billion in 2026.
• The last three Net Cash Flow figures came in at -$2.8 billion (Q2 2026), $4.2 billion (Q1 2026), and -$411.0 million (Q4 2025), per Business Quant data.